NeuroSense Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO NeuroSense Therapeutics is Alon Ben-Noon, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.01M, bestaande uit 36.2% salaris en 63.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 15.83% van de aandelen van het bedrijf, ter waarde $ 2.77M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 2.9 jaar.

Belangrijke informatie

Alon Ben-Noon

Algemeen directeur

US$1.0m

Totale compensatie

Percentage CEO-salaris	36.2%
Dienstverband CEO	8.8yrs
Eigendom CEO	15.8%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	2.9yrs

Recente managementupdates

Recent updates

We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Jul 06

NeuroSense climbs 66% after early data supporting Alzheimer’s candidate

Jun 30

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

Mar 31

NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

Mar 22

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

Dec 22

Analyse CEO-vergoeding

Hoe is Alon Ben-Noon's beloning veranderd ten opzichte van NeuroSense Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	US$1m	US$367k	-US$10m
Sep 30 2023	n/a	n/a	-US$11m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$2m	US$410k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 1.01M ) Alon } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Alon is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Alon Ben-Noon (45 yo)

8.8yrs

Tenure

US$1,013,000

Compensatie

Mr. Alon Ben-Noon is the Co-Founder of NeuroSense Therapeutics Ltd. and serves as its Chief Executive Officer since 2016 and Director since February 2017. Mr. Ben-Noon served as Chair of Board of Directors...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Alon Ben-Noon	Co-Founder	8.8yrs	US$1.01m	15.83% $ 2.8m
Or Eisenberg	Chief Financial Officer	3.4yrs	US$1.02m	2.36% $ 414.0k
Hagit Binder	Chief Operation Officer	no data	US$266.62k	0.11% $ 19.8k
Niva Russek-Blum	Chief Technology Officer	1.5yrs	US$291.62k	0.34% $ 58.9k
Ferenc Tracik	Chief Medical Officer	2.9yrs	US$918.00k	0.63% $ 110.7k
Yael Barak	VP of Quality & Compliance	2.8yrs	geen gegevens	geen gegevens
Keren Pushett	Head of HR	1.4yrs	geen gegevens	geen gegevens
Eidan Loushi	C.R.A.	1.8yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

45.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NRSN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Alon Ben-Noon	Co-Founder	7.8yrs	US$1.01m	15.83% $ 2.8m
Mark Leuchtenberger	Independent Chairman of the Board	3.1yrs	US$1.48m	0.33% $ 57.6k
Cary Claiborne	Independent External Director	2.9yrs	US$104.00k	0.12% $ 21.6k
Christine Pellizzari	Independent External Director	2.9yrs	US$104.00k	0.12% $ 21.6k
Jeremy Shefner	Chair of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Revital Mandil-Levin	Director	2.8yrs	US$91.00k	0.15% $ 25.7k
Merit Cudkowicz	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Roy Golan	Director	less than a year	geen gegevens	geen gegevens
Jinsy Andrews	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Orla Hardiman	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Jeffrey Rosenfeld	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NRSN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.

NeuroSense Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

NeuroSense Therapeutics Ltd., Annual General Meeting, Jun 27, 2024

High number of new and inexperienced directors

Less than half of directors are independent

NeuroSense Therapeutics Ltd., Annual General Meeting, Jun 21, 2022

Less than half of directors are independent

Recent updates

NeuroSense Therapeutics Ltd. Advances Plans for Early Commercialization of ALS Treatment in Canada

Neurosense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

New major risk - Share price stability

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Ltd. has filed a Follow-on Equity Offering in the amount of $2.524437 million.

NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding

NeuroSense Therapeutics Ltd. Announces Positive Biomarker Data from ALS Phase 2B Clinical Trial

NeuroSense Therapeutics Ltd. Announces Additional Positive Results from its 12-Month PARADIGM Phase 2b Study of PrimeC in ALS Patients

NeuroSense Therapeutics Ltd. Reports Statistically Significant Results from the 12-Month Paradigm Study Evaluating PrimeC in People Living with Amyotrophic Lateral Sclerosis

New major risk - Shareholder dilution

NeuroSense Therapeutics Ltd., Annual General Meeting, Jun 27, 2024

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense Therapeutics Ltd. announced that it expects to receive $4.47 million in funding

NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely

Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Neurosense Therapeutics Ltd. Reports Additional Positive Efficacy Data from Further Evaluation of Its Phase 2B Als Trial

Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?

NeuroSense Therapeutics Ltd.'s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

New major risk - Share price stability

New major risk - Revenue and earnings growth

Neurosense Receives U.S. Fda Confirmation of Cmc Strategy for Primec in Preparation for Pivotal Phase 3 in Als and Commercial Readiness

Neurosense Therapeutics Ltd. Announces Results of Non-Sponsored in Vitro Study of PrimeC in Amyotrophic Lateral Sclerosis

European Medicines Agency Grants the Small and Medium-Sized Enterprise Status of Neurosense Therapeutics Ltd

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

High number of new and inexperienced directors

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

NeuroSense Therapeutics Ltd. Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

NeuroSense Therapeutics Ltd. Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study

NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

NeuroSense Therapeutics Ltd. Receives Regulatory Approval to Commence Patient Enrollment in Italy for Its Phase 2B Trial in Als

Neurosense Receives FDA Clearance of IND for Its ALS Phase 2b Study

Less than half of directors are independent

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

Neurosense Therapeutics Ltd. Announces Positive Primec Toxicology Data Supportive of Current Phase IIb Paradigm Als Clinical Trial

NeuroSense Therapeutics GAAP EPS of -$0.55

NeuroSense Therapeutics Ltd. Reports Strong Patient Enrollment in Its Phase IIb PARADIGM Trial for Its Lead Drug Candidate PrimeC for the Treatment of ALS

NeuroSense Joins Everything ALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Neurosense Therapeutics Ltd. Reports Completion of the "In-Life" Phase of Its 90-Day Glp Toxicology Study Successfully

NeuroSense climbs 66% after early data supporting Alzheimer’s candidate

NeuroSense Therapeutics Ltd. Reports Positive Results from Stage III ALS Biomarker Study

NeuroSense Therapeutics Ltd. Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

NeuroSense Therapeutics Ltd., Annual General Meeting, Jun 21, 2022

Less than half of directors are independent

NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

NeuroSense Therapeutics Ltd. has completed an IPO in the amount of $12 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd